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Induction of Targeted Cell Migration by Cutaneous
Administration of a DNA Vector Encoding a
Biologically Active Chemokine CCL21
Ahmad Jalili1, Mikhail Pashenkov1,3, Ernst Kriehuber1, Christine Wagner1, Hideki Nakano2, Georg Stingl1
and Stephan N. Wagner1
Skin inflammation can induce local expression of CCL21, which is subsequently drained to lymph nodes (LNs)
influencing their cellular composition. To determine whether the same can be achieved by dermal
administration of a plasmid DNA (pDNA) encoding CCL21, we generated a pDNA-based gene construct
allowing high-level expression of CCL21. Expression and secretion of biologically active CCL21 were confirmed
in vitro by immunohistochemistry, western blot analysis, ELISA, and transwell chemotactic assays. In vivo
experiments showed cellular expression of transgenic CCL21 after particle-mediated gene gun delivery of
pDNA into skin. CCL21 was expressed in the epidermis, consequently secreted into the upper dermis, and
transported into the draining LNs, which resulted in increased CCL21 concentration, total cell number, and
frequencies of CD11cþ DCs and CD4þ /CD62Lþ naı¨ve, CD4þ /CD62L, and CD8þ /CD62L effector memory T-
cells (expressing CCL21 receptors CCR7 or CXCR3), as well as retention of adoptively transferred T-lymphocytes,
in the draining LNs of plt/plt mice (lacking endogenous expression of CCL21). Our studies show that
biologically active CCL21 can be overexpressed by genetic means in vitro and in vivo. This strategy allows
reconstitution of a genetic defect and colocalization of different cell types in the secondary lymphoid organs,
an important prerequisite for targeted cell migration.
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INTRODUCTION
The skin and its draining peripheral lymph nodes (PLNs)
comprise a distinct immunological compartment, continu-
ously exposed to a potentially pathogenic exogenous
environment. Within this immunological compartment,
skin-residing dendritic cells (DCs) function as sentinels that
acquire antigens and initiate antigen-specific adaptive
immune responses as diverse as peripheral tolerance
and immunity in the draining PLNs where they meet naı¨ve
T-lymphocytes (Steinman and Nussenzweig, 2002; Bancher-
eau et al., 2003; Steinman, 2003).
Chemokines are a group of small (B8–14 kDa) and
structurally related molecules that have originally been
described to regulate cell trafficking through interactions
with a subset of seven transmembrane, G protein-coupled
receptors (Rossi and Zlotnik, 2000; Colditz et al., 2007).
These chemokine–chemokine receptor interactions have a
fundamental role in the development, homeostasis, and
induction of innate and adaptive immune responses (Zlotnik
and Yoshie, 2000). Chemokines have been broadly classified
into ‘‘inflammatory’’ and ‘‘homeostatic’’ chemokines on the
basis of the site of production and induction of stimuli
(Zlotnik and Yoshie, 2000; Laing and Secombes, 2004).
Whereas inflammatory chemokines share several receptors
and are induced to high-level expression by inflammatory
stimuli, homeostatic chemokines are usually receptor-
restricted and are primarily involved in the homeostasis of
leukocyte traffic and lymphoid cell localization.
Secondary lymphoid-organ chemokine (CCL21) has long
been regarded as a homeostatic chemokine as it is
constitutively expressed in mice by (i) stromal cells in the
T-cell-rich zones of PLNs (Gunn, 2003); (ii) afferent
lymphatic endothelial cells; and (iii) high endothelial venules
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(HEVs). In humans, CCL21 is expressed by stromal cells in the
T-cell-rich zones of PLNs and subsequently exposed on HEVs
(Carlsen et al., 2005). The CCL21 receptor, CCR7, is
expressed on mature DCs, naı¨ve T-cells, and a subset of
memory T-cells (Ebert et al., 2005; Yoneyama et al., 2005). In
the steady state, CCL21 is essential for coordination of
CCR7þ cell migration, that is, directional migration and
positioning of lymphocytes and DCs within the T-cell zone of
secondary lymphoid organs (SLOs). The importance of this
chemokine–chemokine receptor interaction under homeo-
static conditions is best illustrated in studies of mice lacking
either this chemokine (Gunn et al., 1999) or its receptor
(Forster et al., 1999). plt/plt mice harbor a spontaneous
mutation that abolishes CCL21’s expression in lymphatic
tissues (Gunn et al., 1999; Luther et al., 2000). As a result,
antigen-presenting DCs and naı¨ve T-cells fail to enter the
T-cell zones of SLOs (Gunn et al., 1999). A similar
phenomenon can be observed in CCR7-deficient mice
(Forster et al., 1999). In these mice, the overall micro-
architecture of SLOs is altered with prominent B-cell follicles
with considerably enlarged germinal centers and significant
reduction or even absence of T-cell areas (Forster et al., 1999).
These alterations are thought to be caused by the impaired
entry and retention of CCR7-expressing, antigen-presenting
DCs and CD4þ /CD62Lþ naı¨ve/central memory T-lympho-
cytes (Forster et al., 1999). Consistently, CCR7 has been
implicated in the migration of chronic lymphocytic
leukemia cells into the LNs and the development of disease-
associated peripheral lymphadenopathy in humans (Till et al.,
2002).
Colocalization of DCs and naı¨ve/central memory T-cells in
the PLNs is a pre-requisite for the induction of immune
responses (Banchereau et al., 2003). It has been previously
shown that when recombinant CCL21 was injected intracu-
taneously into plt/plt mice, the chemokine entered the
afferent lymph vessels and accumulated in the draining PLNs
leading to luminal presentation of CCL21 in a subset of HEVs
(Stein et al., 2000).
In this study we show that gene gun-mediated dermal
administration of a plasmid DNA (pDNA) encoding a
biologically active CCL21 chemokine leads to the expression
of the chemokine in the epidermis and its subsequent
drainage into PLNs, leading to accumulation of CCR7-
expressing DCs and naı¨ve/central memory T-cells, as well
as CXCR3-expressing CD4þ /CD62L and CD8þ /CD62L
effector T-cells, in these organs. Additionally, transgenic
CCL21 shows biological activity on DCs, including induction
of antigen uptake and upregulation of CD40 surface
expression (previously described to be responsible for
survival of migrating DCs).
RESULTS
Transfection with murine CCL21 pDNA induces the expression
and secretion of CCL21
After translation in the endoplasmic reticulum, chemokines
are transported to the Golgi complex and subsequently to
secretory granules (Nickel, 2003) where they have been
shown to be stored. Upon stimulation with inflammatory
cytokines such as tumor necrosis factor, signaling pathways
such as mitogen-activated protein kinase-signaling pathways
extracellular signal-regulated kinase and p38 are activated
that induce rapid transport of stored chemokines to the cell
surface and secretion into the pericellular space (Chensue,
2001; Wong et al., 2006). To determine whether transfection
with pVR1012-mCCL21-IRES-EGFP (Figure 1a) and
pVR1012-mCCL21/EGFP (Figure 1b) pDNA induces an
intracellular expression and trafficking pattern of CCL21
comparable to physiological expression levels, transfected
COS-7 cells were monitored for expression, intracellular
distribution, and secretion of transgenic murine CCL21
(mCCL21).
In western blot analysis of protein lysates derived from
COS-7 cells transfected with pVR1012-mCCL21-IRES-EGFP,
the expected 15-kDa band of mCCL21 (Christopherson et al.,
2001) could be detected (Figure 1c). Transfection with
pVR1012-mCCL21/EGFP pDNA encoding a chimeric
mCCL21/EGFP resulted in the expression of a protein with
a higher molecular weight of around 75 kDa, corresponding
to the 15-kDa molecular weight of mCCL21 plus the 60-kDa
molecular weight of enhanced green fluorescent protein
(EGFP) (Shigaki et al., 2005; Figure 1c).
Immunocytochemistry of COS-7 cells transfected with
pVR1012-mCCL21-IRES-EGFP uncovered a cytoplasmic ex-
pression pattern of mCCL21 (Figure 1d). As expected,
confocal laser-scanning microscopy detected a similar
expression pattern of the separately translated EGFP (Figure
1e). To study the subcellular distribution of transgenic
mCCL21 in more detail, we transfected COS-7 cells with
the pVR1012-mCCL21/EGFP pDNA encoding a chimeric
mCCL21/EGFP protein. Confocal microscopy showed
mCCL21/EGFP to be particularly enriched in two ways:
juxtanuclearly, probably in the Golgi complex, and juxta-
membraneously in the secretory granules (Figure 1f). These
data are in accordance with the intracellular expression and
secretion pathway described for chemokines (Nickel, 2003).
mCCL21 could also be detected in the supernatants of
COS-7 cells transfected with pVR1012-mCCL21-IRES-EGFP
pDNA. As measured by ELISA 48 hours after transfection,
0.5106 cells transfected with 5 mg of pVR1012-mCCL21-
IRES-EGFP were able to secrete around 60 ng ml1 of
mCCL21, whereas supernatants from cells transfected with
control pVR1012 pDNA did not contain mCCL21 at
detectable amounts (o10 pg ml1) (data not shown).
pDNA-encoded murine CCL21 is functionally active
First, we determined whether transgenic CCL21 binds to cells
expressing CCR7. Bone marrow-derived dendritic cells
(BMDCs) were generated as described earlier (Jalili et al.,
2004). Around 55% of these cells express CCR7 as
determined by flow-cytometric analysis (Figure 2a3). COS-7
cells were transfected with pVR1012-mCCL21/EGFP, encod-
ing chimeric mCCL21/EGFP, and supernatants were collected
48 hours later. As indicated by flow cytometry, approximately
46% of BMDCs (incubated with above mentioned super-
natants) bound to chimeric mCCL21/EGFP (Figure 2b2).
Binding could be completely blocked by pre-incubation of
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supernatants with anti-mCCL21 neutralizing antibody (Ab)
(Figure 2b3).
We next determined whether plasmid-encoded murine
CCL21 also mediates the chemotaxis of CCR7-expressing
murine cell populations in standard transwell migration
assays. In these assays, supernatants of COS-7 cells were
collected 48 hours after transfection with pVR1012-mCCL21-
IRES-EGFP and compared with different concentrations of
recombinant mCCL21 (rmCCL21) protein for their induction
of chemotaxis of splenocytes (containing both DCs and
naı¨ve/central memory T-cells) isolated from wild-type BALB/c
mice. As indicated by flow-cytometric analysis, approxi-
mately 50% of BALB/c splenocytes express CCR7 and
approximately 25% express CD4/CD62L representing naı¨ve/
central memory T-cells (data not shown). rmCCL21 protein
induced concentration-dependent chemotaxis of splenocytes
(Figure 2c) as did supernatants of COS-7 cells transfected
with pVR1012-mCCL21-IRES-EGFP (supernatants of COS-7
cells transfected with pVR1012-mCCL21-IRES-EGFP contain-
ing B60 ng ml1 of CCL21 were as effective as 1 mg ml1 of
rmCCL21 presumably because of post-translation modifica-
tion of the transgenic CCL21, making it biologically more
active, a phenomenon absent in the case of rmCCL21;
Figure 2c, Po0.001, analysis of variance (ANOVA) test with
Tukey post-test). In contrast, chemotaxis could not be
observed with supernatants derived from control pVR1012-
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Figure 1. mCCL21 is efficiently expressed and secreted by genetic means in vitro. (a) pVR1012-mCCL21-IRES-EGFP, a bicistronic pDNA vector expressing
mCCL21 and EGFP under the pCMV promoter, with two transgenes separated by an IRES sequence allowing efficient translation of the second transgene
upon transfection into cells. MCS indicates the multiple cloning site of the pDNA. (b) pVR1012-mCCL21/EGFP expresses mCCL21, which is tagged at its
N-terminus to EGFP. (c) Western blot analysis of protein lysates derived from COS-7 cells transfected with pVR1012-mCCL21/EGFP showing expression of
mCCL21 with a molecular weight of about 60 kDa higher than the non-chimeric mCCL21 expressed by pVR1012-mCCL21-IRES-EGFP, confirming successful
tagging of mCCL21 with EGFP. (d, e) Transfection of COS-7 cells shows efficient expression of both mCCL21 and EGFP as shown by mCCL21
immunocytochemistry and fluorescence microscopy for EGFP, respectively. (f) Immunofluorescence microscopy of COS-7 cells transfected with pVR1012-
mCCL21/EGFP shows subcellular localization of mCCL21/EGFP chimera juxtanuclearly, probably in the Golgi complex, and juxtamembraneously in secretory
granules. Bar¼ panel d: 100 mm; panels e and f: 10mm.
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IRES-EGFP-transfected COS-7 cells (Figure 2c). Chemotaxis of
splenocytes toward supernatants derived from COS-7 cells
transfected with pVR1012-mCCL21-IRES-EGFP could be
blocked by anti-mCCL21 neutralizing Ab (Figure 2c). Recom-
binant mCCL21 protein also induced a dose-dependent
enrichment for CCR7-expressing cells in the transmigrated
splenocyte population, as indicated by flow-cytometric analy-
sis for CD4þCD62Lþ naı¨ve/central memory T-cells (40% as
compared with 20% of input splenocytes). The same phenom-
enon could be observed by supernatants of COS-7 cells
transfected with pVR1012-mCCL21-IRES-EGFP (Figure 2d).
CCL21 induces FITC-dextran uptake by BMDCs and upregulates
CD40 expression on BMDCs without evidence of maturation
To study whether CCL21 is able to induce the maturation of
DCs, BMDCs were treated for 24 hours with rmCCL21 (dose
range 0.1–5 mg ml1) as well as with supernatants of COS-7
cells collected 48 hours after transfection with pVR1012-
mCCL21-IRES-EGFP (containing B60 ng ml1 mCCL21 as
measured by ELISA). Lipopolysaccharide (LPS)-treated
BMDCs served as positive control (Hemmi and Akira,
2005). While LPS upregulated the surface expression of
CD80, CD86, and CCR7; induced morphological changes
associated with maturation such as increase in the cell-
surface area and decrease in the granularity; and enhanced
the allostimulatory capacity of BMDCs in mixed-leukocyte
reaction assays (data not shown) (Granelli-Piperno et al.,
2004), rmCCL21 or mCCL21 derived from the supernatants of
COS-7 cells did not show any of these effects (data not
shown). In contrast, we observed significant upregulation
(Po0.001, ANOVA test with Tukey post-test) of the surface
expression of CD40 (Figure 3b) upon treatment with
rmCCL21 or mCCL21 derived from the supernatants of
COS-7 cells, a phenomenon also observed by treatment of
these cells with LPS (Figure 3c). These in vitro data were
supported in vivo by using the pVR1012-mCCL21 pDNA
vector expressing mCCL21 administered to the skin of BALB/
c mice using the helium-based gene gun technique. There,
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Figure 2. pDNA-encoded murine CCL21 is functionally active. (a) Cultured BMDCs from wild-type BALB/c mice express CD11c and CCR7 as measured by
flow cytometry (2 and 3, respectively). The isotype-matched Ab shows no unspecific binding (1). (b) These BMDCs bind to chimeric mCCL21/EGFP (2) when
incubated with the supernatants of COS-7 cells transfected with pVR1012-mCCL21/EGFP, as shown by flow cytometric analysis for EGFP fluorescence. No
fluorescence signal could be observed when BMDCs were incubated with supernatants derived from COS-7 cells transfected with the control pVR1012-IRES-
EGFP (1). Pre-incubation of supernatants of COS-7 cells transfected with pVR1012-mCCL21/EGFP with neutralizing anti-mouse CCL21 Ab leads to complete
inhibition of binding (3). One representative of two independent experiments is shown. (c) In transwell migration assays, freshly isolated splenocytes from
wild-type BALB/c mice migrated toward the supernatants of COS-7 cells transfected with pVR1012-mCCL21-IRES-EGFP as well as rmCCL21. Supernatants
collected from pVR1012-mCCL21-IRES-EGFP-transfected COS-7 cells for 48 hours were as effective as 1 mg ml1 rmCCL21. The neutralizing anti-mCCL21 Ab
completely blocked migration. (d) Note the preferential enrichment of the transmigrated cell population for CD4þ /CD62Lþ T-cells, known to express CCR7,
by transgenic mCCL21 at levels comparable to recombinant mCCL21. Data collected from three experiments; the error bars indicate the SD.
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we observed significant upregulation of surface expression of
CD40 on CD11cþ DCs derived from pVR1012-mCCL21-
treated mice (Figure 3g) as compared with mock pDNA
(pVR1012)-treated or untreated mice (Figure 3e and f,
respectively, Po0.001, ANOVA test with Tukey post-test).
rmCCL21, as well as mCCL21 derived from supernatants of
COS-7 cells, significantly induced the uptake of FITC-dextran
by BMDCs (Figure 3d, Po0.001, ANOVA test with Tukey
post-test).
Gene gun-mediated administration of mCCL21 pDNA to the
skin leads to the expression of CCL21 in the epidermis, with
subsequent secretion into the dermis and accumulation in the
draining PLNs
Next, we investigated whether transgenic CCL21 expression
can be achieved in vivo upon gene gun-mediated adminis-
tration of a CCL21-encoding plasmid. To identify cells that
are targeted by this approach, we administered the pVR1012-
mCCL21-IRES-EGFP construct into mice and performed an
expression analysis of transgenic EGFP, which, after transfec-
tion is known to remain intracellularly and not to be secreted
into the surroundings of a transfected cell (Ogura et al.,
2004). Laser-scanning microscopy performed 24 hours after
cutaneous administration of pVR1012-mCCL21-IRES-EGFP
showed EGFP expression in the epidermis (Figure 4a),
including areas surrounding hair follicles, but not in cell
types residing in the dermis. In time-course experiments,
expression of transgenic EGFP was highest at 24 hours,
gradually decreased on days 3 and 7 after gene gun-mediated
administration, and was completely lost on day 14 (Figure 4a
and data not shown, respectively). At neither time point was
EGFP expression detected in the dermis. These data argue for
an in vivo expression pattern of pVR1012-mCCL21-IRES-
EGFP, with restriction to keratinocytes of the epidermis, and
against a significant transfection of other cell types residing in
the dermis.
We then determined whether administration of mCCL21
pDNA leads to expression of the encoded transgene in the
skin. Using the helium-based gene gun technique the
abdominal area skin of plt/plt BALB/c mice received three
non-overlapping shots of 1 mg pVR1012-mCCL21-IRES-EGFP
or control pVR1012-mock and was analyzed for the
expression of mCCL21 24 hours later. As expected, pro-
nounced intracellular immunoreactivity could be observed in
the keratinocytes of the epidermis after administration of
pVR1012-mCCL21-IRES-EGFP but not control pVR1012-
mock (Figure 4b). Interestingly, diffuse immunostaining was
also present throughout the dermis after administration of
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Figure 3. CCL21 induces the expression of CD40 on DCs. (a–c) CD40 expression by BMDCs generated in the presence of GM-CSF and IL-4. (b, c)
rmCCL21 (1 mg ml1) induces the expression of CD40 by BMDCs, as does LPS. (d) rmCCL21 (1 mg ml1) increased the uptake of FITC-dextran by BMDCs in
contrast to treatment with LPS (1 mg ml1). Data collected from three experiments; the error bars indicate the SD; **Po0.001, ANOVA test with Tukey post-test.
For each graphical plot, identical results were obtained using mCCL21 derived from supernatants of COS-7 cells transfected with pVR1012-mCCL21-IRES-EGFP
(data not shown). (e–g) CD40 expression by skin CD11cþ DCs. Gene gun-mediated administration of pVR1012-mCCL21 to the skin led to significant
upregulation of CD40 surface expression by skin CD11cþ DCs (g) in contrast to administration of pVR1012-mock (n¼ 3). (e) Untreated skin.
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pVR1012-mCCL21-IRES-EGFP (Figure 4b), secretion of the
transgenic CCL21 from the transfected keratinocytes. Again,
this phenomenon could not be observed after administration
of control pVR1012-mock (Figure 4b), thereby excluding the
possibility that endogenous mCCL21 may have been induced
by the gene gun technique itself.
We further analyzed whether in vivo transfected kerati-
nocytes are able to secrete transgenic CCL21. Single-cell
suspensions of total skin were prepared 24 hours after gene
gun-mediated administration of pVR1012-mCCL21-IRES-
EGFP or control pVR1012-IRES-EGFP and cultured for
72 hours. In contrast to supernatants of keratinocytes derived
from control pDNA-transfected skin areas, those from
pVR1012-mCCL21-IRES-EGFP-transfected sites contained
mCCL21 (Figure 4c, Po0.001, ANOVA test with Tukey
post-test).
To investigate whether CCL21 transgenically expressed in
the skin is transported to the draining LNs, we administered
pVR1012-mCCL21-IRES-EGFP or pVR1012-IRES-EGFP plasmids
into plt/plt mice, collected the PLNs draining the sites of plasmid
administration, and measured CCL21 in PLN homogenates by
ELISA. The PLNs draining the skin transfected with pVR1012-
mCCL21-IRES-EGFP contained dramatically higher amount of
mCCL21 as compared with those draining the pVR1012-IRES-
EGFP-transfected or untreated skin (Figure 4d, Po0.001,
ANOVA test with Tukey post-test).
Taken together, these data argue for expression of gene
gun-administered CCL21 pDNA in epidermal keratinocytes,
subsequent secretion into the dermis and drainage into
loco-regional LNs.
Gene gun-mediated administration of mCCL21 pDNA to the
skin induces the in vivo migration of DCs, naı¨ve/central
memory, and effector T-cells to the draining LNs
Keratinocyte-derived cytokines are secreted into the dermis,
where they are collected by the lymphatics and subsequently
transported to the draining PLNs (Palframan et al., 2001). We
therefore hypothesized that upon pVR1012-mCCL21-IRES-
EGFP administration to the skin, (i) transgenic CCL21 should
not only be expressed in keratinocytes and secreted into the
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Figure 4. Epidermal expression of transgenic CCL21 in the skin upon gene gun-mediated administration of pVR1012-mCCL21-IRES-EGFP in vivo and its
subsequent drainage into PLNs. (a) Expression of EGFP is restricted to the epidermis, and no fluorescence is detected after application of the pVR1012-mock
vector. Skin sections were obtained 24 hours after pDNA administration. (b) Day-1 cryosections were immunostained using a polyclonal goat anti-mouse CCL21
Ab. APAAP method: hematoxylin counterstaining. Note that CCL21 immunoreactivity in the epidermis is similar to the EGFP expression pattern. In addition,
CCL21 immunoreactivity can be observed in the dermis, most probably representing CCL21 secreted from the epidermis into the dermis. No immunoreactivity
after application of pVR1012-mock vector. Bar¼ panels a and b: 100 mm. One representative of three independent experiments is shown. (c) In vitro cultured
whole single-cell suspension of skin 3 days after pVR1012-mCCL21-IRES-EGFP application. Secretion of mCCL21 as measured by mCCL21 ELISA in
supernatants. The data are from three experiments (n¼ 3 per group); the error bars indicate the SD; **Po0.001, ANOVA test with Tukey post-test. (d) Inguinal
LNs were isolated 3 days after pVR1012-mCCL21-IRES-EGFP or control pVR1012-IRES-EGFP application into the abdominal skin of plt/plt mice. LNs were
homogenized and the concentration of mCCL21 was measured. The total concentration of CCL21 per LN is expressed in nanograms, n¼ 3; the error bars
indicate the SD; **Po0.001, ANOVA test with Tukey post-test.
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dermis, but also be drained to the loco-regional LNs and, as a
result, (ii) skin-derived transgenic CCL21 should promote the
in vivo migration of CCR7þ mature CD11cþ DCs and
CD4þ /CD62Lþ naı¨ve/central memory T-lymphocytes into
the PLNs. To test whether skin-derived CCL21 can influence
cell migration in the PLNs, pVR1012-mCCL21-IRES-EGFP
and control pVR1012-IRES-EGFP were administered to the
abdominal skin of plt/plt mice and draining, that is, inguinal
PLNs were collected at different time points thereafter. At day
1 after administration, PLNs draining the pVR1012-mCCL21-
IRES-EGFP administration sites contained significantly higher
total cell numbers than those draining the control pVR1012-
IRES-EGFP administration sites or untreated skin (P-
value¼0.067 and 0.0033, respectively; Figure 5a). This
effect was lost within 3–7 days after pDNA administration
(Figure 5a). As an additional measure of the biological
activity of transgenic mCCL21, we analyzed PLNs for
differences in the cellular composition with respect to
CCR7-expressing cell types, namely CD11cþ DCs and
CD4þ /CD62Lþ naı¨ve/central memory T-cells. PLNs draining
the pVR1012-mCCL21-IRES-EGFP administration sites con-
tained a significantly higher percentage of CD11cþ DCs than
those draining the control pVR1012-IRES-EGFP administra-
tion sites or untreated skin (P-value¼ 0.041 and 0.019,
respectively; Figure 5b). The same phenomenon could
also be observed for CD4þ /CD62Lþ naı¨ve/central memory
T-cells (P-value o0.001; Figure 5c). The highest increase in
the percentage of CD11cþ DCs and CD4þ /CD62Lþ naı¨ve/
central memory T-cells was observed on day 3 after
administration of pVR1012-mCCL21-IRES-EGFP (Figure 5b
and c, respectively). This effect was lost within 7–14 days
after pDNA administration (data not shown). We observed
also a concomitant increase in the number of CD4þ /CD62L
and CD8þ /CD62L cells (Figure 6a and b).
As an additional independent measure of induction of
targeted cell migration to LNs by cutaneous CCL21 pDNA
administration, we performed adoptive cell transfer experi-
ments using plt/plt mice. In wild-type BALB/c mice, the
CD62Lþ subpopulation of splenocytes is known to migrate
into the PLNs after adoptive transfer into the tail vein (Stein
et al., 2000), a phenomenon not observed in plt/plt mice
(Stein et al., 2000). We therefore administered pVR1012-
mCCL21-IRES-EGFP and control pVR1012-IRES-EGFP to the
abdominal skin of plt/plt mice and after 24 hours—the time
point of peak-level expression of the transgene in the skin—
the injected syngeneic wild-type BALB/c-derived 5,6-carbox-
yfluorescein diacetate succinimidyl ester (CFSE)-labeled
splenocytes into the tail vein of these animals. Three hours
later, the PLNs and spleen were analyzed for the presence of
CFSE-labeled splenocytes. The PLNs draining the pVR1012-
mCCL21-IRES-EGFP administration site contained a signifi-
cantly higher number of CSFE-labeled cells than those
draining the control pVR1012-IRES-EGFP administration site
or untreated skin (P-valueo0.05; Figure 7a). In non-draining
SLOs such as the spleen, induction of cell migration as
indicated by increased CFSE-labeled cell numbers could not
be observed (P-value 40.05; Figure 7b).
We also analyzed whether DCs are capable of migrating
out of skin samples expressing transgenic CCL21. Skin
samples were isolated 1 day after in vivo gene-gun-mediated
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administration of pVR1012-mCCL21-IRES-EGFP or control
pVR1012-IRES-EGFP and cultured for 72 hours in vitro. In
contrast to supernatants of skin samples derived from control
pDNA-transfected skin areas, those from pVR1012-mCCL21-
IRES-EGFP-transfected sites contained significantly higher
number of CD11cþ DCs (see Supplementary Figure S1 online).
DISCUSSION
Gene gun application of pDNA expressing CCL21 is an easy,
practical, and cost-effective approach for dermal administra-
tion of CCL21 with a good bioavailability. Our data show that
skin-derived CCL21 (by gene gun application of pDNA
expressing CCL21) crucially influences the cellular composi-
tion of the draining PLNs. This strategy leads to preferential
accumulation of mCCL21 in—and recruitment of CCR7-
expressing, CD11cþ DCs and CD4þ /CD62Lþ naı¨ve/central
memory T-cells, as well as CXCR3-expressing, CD4þ /
CD62L and CD8þ /CD62L effector memory T-cells,
into—the PLNs. We postulate that this is a direct function
of the expression kinetics of CCL21 after application of
CCL21–pDNA into the skin. Increased migration of DCs with
upregulated surface expression of CD40 and naı¨ve/central
memory T-cells (principal players executing the adaptive
immune responses) to the PLNs would lead to the delivery of
higher amounts of antigens. This would be followed by
stronger and longer-lasting (prolonged DC survival) cellular
and humoral (through B-cell activation and Ig class switch-
ing) immune responses. The expression of CD62L by naı¨ve/
central memory T-cells argues for the migration of these cells
from the blood through HEVs rather than enhanced recruit-
ment through afferent lymphatics from the skin. In accor-
dance with this, we observed enrichment of CCR7-expressing
splenocytes in the PLNs draining the CCL21-expressing skin
after intravenous adoptive transfer, but no recruitment of
splenocytes to the site of CCL21 expression in the skin (data
not shown). Consistently, CCL21 has been described to be
presented on the luminal surface of a subset of PLN HEVs
after intracutaneous application, where it promotes lympho-
cyte function-associated protein-1-mediated T-cell adhesion
(Stein et al., 2000). We did not observe accumulation of DCs
at the site of CCL21 expression in the skin, which is
presumably because of continuous influx of DC precursors
into the skin and emigration into draining the LNs, the two
processes balancing each other (data not shown).
Interestingly, we observed that the frequencies of
CD4þ /CD62L and CD8þ /CD62L effector memory
T-lymphocytes were also significantly increased in the PLNs
draining the VR1012-mCCL21-IRES-EGFP administration site.
These cell populations may represent effector memory T-cells
that are known to downregulate CD62L expression after
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priming in SLOs (Roberts et al., 2005). These cells express
also CXCR3, recently identified to induce chemotaxis toward
CCL21 in murine and human microglial cells (Soto et al.,
1998; Rappert et al., 2002; Dijkstra et al., 2004). It has been
documented that these cells express CXCR3 (Mohan et al.,
2005). Rappert et al. (2002) has recently shown that CCL21
has the capability to bind to CXCR3 and induce chemotaxis
in microglia. CD62L (L-slectin), is an adhesion molecule
found on most leukocytes, and has a primary role in
mediating initial leukocyte interaction with the activated
vascular endothelium of HEVs and subsequent extravasation
of these cells (Springer, 1995). Lack of CD62L expression by
CD4þ /CD62L and CD8þ /CD62L effector memory cells
possibly excludes their LN entry through HEVs. We speculate
that these cells have presumably entered the PLNs through
afferent lymphatics under a CCL21 gradient. Migration of
effector T-cells through this path has been documented
previously (Bromley et al., 2005).
These data show that, within this distinct immunological
compartment, the skin directly influences the cellular
composition of the draining PLNs with regard to
CD11cþ DCs and T-cells through expression and secretion
of CCL21. As CCL21’s expression is dramatically induced
during skin inflammation and as the numbers of CCR7þ cells
in the PLNs seem to be a direct function of the amount
of skin-expressed CCL21, CCL21 may constitute a direct link
of skin inflammation and induction of antigen-specific
immunity.
Our data show that CCL21 induces CD40 expression but
not maturation of DCs as defined by morphology (granularity
and size), phenotype (CD80/86-, CCR7- expression), and
function (mixed-leukocyte reaction). To our knowledge this is
previously unreported. CD40 ligation has originally been
reported to induce the expression of CD80 and CD86 co-
stimulatory molecules on DCs (Caux et al., 1994; Cella et al.,
1996; Koch et al., 1996; Flores-Romo et al., 1997), to
enhance DC survival (Quezada et al., 2004), migration
(Moodycliffe et al., 2000), and to avoid suppression of the
immune responses (Grohmann et al., 2001; Serra et al.,
2003). In this regard, the expression and function of CD40
seem to accompany features associated with maturation of
DCs. However, a distinctive role for CD40 is indicated
in vitro, where BMDCs show better induction of T-cell
responses by CD40 ligation than by other maturation stimuli
(Labeur et al., 1999; Kelleher and Beverley, 2001). This is
supported by the in vivo a-GalCer model for DC maturation,
where expression of the major histocompatibility complex–-
peptide complex and CD86 does not lead to the induction of
CD4þ T-helper cell-I- and CD8þ cytolytic T-lymphocyte-
mediated immunity in the absence of the CD40–CD40 ligand
interaction (Fujii et al., 2004). Consistently, increased
expression of CD80 and CD86 on DCs alone did not lead
to immunity in the absence of CD40 ligation in tumor
necrosis factor-a-induced skin inflammation (O’Sullivan and
Thomas, 2003; Fujii et al., 2004). Most recently, CD40 has
been described to be essential for CD4þ memory T-cell
expansion and effector cell differentiation, but dispensable
for CD4þ memory T-cell survival and proliferation (MacLeod
et al., 2006). These results may help to explain why plt/plt
mice can mount CD4þ T-cell responses that may be of
slower kinetics but higher magnitude than those in wild-type
mice (Mori et al., 2001; Junt et al., 2002). Besides the unique
capability of DCs to activate naı¨ve T-cells, these highly
versatile antigen-presenting cells have been shown to directly
induce proliferation and IgM secretion, as well as isotype
switch to g and a, in CD40-activated naı¨ve B-cells (Dubois
et al., 1997; Johansson et al., 2000).
Understanding the mechanisms that control the function
and migration of DCs is crucial for the development of new
treatment approaches for immunological skin diseases as
diverse as autoimmune diseases, skin tumors, skin infections,
and allergic diseases. Maturation stimuli such as microbial
products and agonistic/antagonistic Abs are prime candidates
in the development of novel adjuvants for induction or
modification of immune responses. Induction of antigen
uptake and CD40 expression on DCs and spatial and
functional segregation of these cells and naı¨ve/central
memory T-cells in a defined immunological compartment
(such as PLNs) is a pre-requisite for induction of proper
immune responses. Expression of CCL21 through administra-
tion of pDNA could have important implications on the
design of future immunotherapeutic strategies, including
those using DC-based cellular cargo delivery.
MATERIALS AND METHODS
Animals and cell lines
plt/plt mice (Gunn et al., 1999) on BALB/c background were bred
and maintained under specific pathogen-free conditions in the
animal facility of the Medical University of Vienna. Wild-type BALB/c
and C57BL/6 mice were purchased from Harlan Winkelmann GmbH
(Borchen, Germany). Mice aged 6–10 weeks were used in all the
experiments. All animal experiments were approved by the local
ethics committee on animal care and use as well as the Austrian
Ministry of Science and Transportation.
COS-7 cells (African green monkey kidney cells) were obtained
from the American Type Culture Collection (ATCC, Rockville, MD)
and grown in DMEM medium (Invitrogen, San Diego, CA)
supplemented with 10% fetal calf serum (Invitrogen) at 371C in a
humidified atmosphere containing 5% CO2.
Construction of plasmid vectors encoding mCCL21
Plasmid pVR1012-mCCL21-IRES-EGFP, allowing separate
translation of mCCL21 and EGFP from a single bicistronic mRNA
(Figure 1a), was constructed as follows: mCCL21 cDNA
(GenBank accession number: AF001980) was amplified by reverse
transcription–PCR with primers containing BglII restriction sites
(VBC-Genomics, Vienna, Austria; 50 primer: GAAGATCTATGGCT
CAGATGATGACTCT and 30 primer: GAAGATCTCTATCCTCTTG
AGGGCTGT). After restriction digestion with BglII (Roche Diag-
nostics GmbH, Mannheim, Germany), the purified PCR product was
inserted into the BglII-cut plasmid pVR1012 (provided by B Zaugg,
Vical, San Diego, CA) (Hartikka et al., 1996) using the Rapid DNA
Ligation kit (Roche Diagnostics) thereby generating plasmid
pVR1012-mCCL21. The IRES-EGFP cDNA was amplified by PCR
with primers containing XbaI restriction sites (VBC-Genomics; 50
primer: GCTCTAGAGCCACCAAAATCAACGGGA and 30 primer:
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GCTCTAGAGCTCAGGTTCAGGGGGAG) using pIRES2-EGFP (In-
vitrogen) as template. After restriction digestion with XbaI (Roche
Diagnostics), the purified PCR product was inserted into the XbaI-cut
plasmid pVR1012-mCCL21 using the Rapid DNA Ligation kit (Roche
Diagnostics), downstream from the mCCL21 transgene, thereby
generating plasmid pVR1012-mCCL21-IRES-EGFP (Figure 1a).
Correct cDNA sequences were confirmed by DNA sequencing
(VBC-Genomics).
Plasmid pVR1012-mCCL21/EGFP, allowing expression of chi-
meric mCCL21/EGFP (Figure 1b), was constructed as follows:
mCCL21 cDNA (see above) was amplified by reverse transcrip-
tion–PCR with primers containing BglII restriction sites. The 30 primer
contained a mismatch base to replace the stop codon TAG by AAG
(VBC-Genomics; 50 primer: GAAGATCTATGGCTCAGATGAT
GACTCT and 30 primer: GAAGATCTCTTTCCTCTTGAGGGCTGT).
After restriction digestion with BglII (Roche Diagnostics), the purified
PCR product was inserted into the BglII-cut plasmid pVR1012 (Vical)
using the Rapid DNA Ligation kit (Roche Diagnostics). The EGFP
cDNA was amplified by PCR using primers containing XbaI
restriction sites (VBC-Genomics; 50 primer: GCTCTAGAGCC-
CATGGTGAGCAAGGG and 30 primer: GCTCTAGAGCTCAGGTT
CAGGGGGAG) using the plasmid pIRES2-EGFP (Invitrogen) as
template. After restriction digestion with XbaI (Roche Diagnostics),
the purified PCR product was inserted into the XbaI-cut plasmid
pVR1012-mCCL21 (with modified stop codon of mCCL21) directly
downstream from the mCCL21 transgene thereby generating plasmid
pVR1012-mCCL21/EGFP (Figure 1b). Correct cDNA sequences were
confirmed by DNA sequencing (VBC-Genomics).
Plasmids were grown in XL1-Blue competent cells (Stratagene, La
Jolla, CA), prepared, and purified using the Qiagen Endotoxin-Free
Plasmid DNA Isolation kit (Qiagen, Hilden, Germany). The quality
and quantity of purified pDNA was assessed by optical densitometry
at 260 and 280 nm and agarose gel electrophoresis. Expression of
mCCL21, EGFP, and chimeric mCCL21/EGFP was confirmed by
immunocytochemistry, flow cytometry, and immunofluorescence
microscopy after transfection into COS-7 cells (as described under
the following section). Parental plasmids pVR1012 and pVR1012-
IRES-EGFP served as controls.
Transfection, immunocytochemistry, and ELISA
Transient transfection of COS-7 cells with pDNA (pVR1012-
mCCL21-IRES-EGFP, pVR1012-mCCL21/EGFP, pVR1012, and
pVR1012-IRES-EGFP) was performed using the Metafectene trans-
fection reagent (Biontex, Martinsried/Planegg, Germany) according
to the manufacturer’s instructions. A 5-mg weight of plasmid DNA
per 5 105 cells was used. The cells and supernatants were
harvested 48 hours after transfection.
For immunocytochemistry, 1 105 cells were transferred onto
glass slides (cytospin preparations), fixed in 4% paraformaldehyde
(Merck Chemicals, Darmstadt, Germany) in phosphate-buffered
saline (PBS) (Invitrogen), washed in PBS/0.5% Triton X-100 (Merck
Chemicals), and unspecific binding sites were blocked with PBS/
10% goat serum (Invitrogen)/0.1% natrium azide (Merck Chemicals,
later referred to as blocking solution) for 1 hour. Subsequently, slides
were incubated with a goat anti-mouse CCL21 polyclonal Ab
(2mg ml1; R&D Systems, Minneapolis, MN) in blocking solution for
1 hour at room temperature (RT) and alkaline phosphatase-con-
jugated rabbit anti-goat antiserum (Molecular Probes, San Diego,
CA) for 30 minutes at RT. Reactions were developed using Fuchsin
Substrate-Chromogen (Dako, Glostrup, Denmark) according to the
manufacturer’s protocol. Expression of EGFP was analyzed in non-
fixed, non-permeabilized living cells by confocal laser-scanning
microscopy (Axiovert 200M; Carl Zeiss MicroImaging GmbH, Jena,
Germany).
For western blotting, transfected COS-7 cells were washed with
cold PBS (Invitrogen), lysed by treatment with radioimmunopreci-
pitation assay buffer (50 mM Tris base (Merck Chemicals), 150 mM
NaCl (Merck Chemicals), 1% NP-40 (ThermoFisher Scientific,
Waltham, USA), 0.25% sodium deoxycholate (Merck Chemicals),
1 mM EDTA (Sigma-Aldrich, Vienna, Austria)) in the presence of a
protease inhibitor cocktail (Complete, Mini Protease Inhibitor
Cocktail Tablets; Roche Diagnostics). Protein concentration was
measured using a bicinchoninic acid protein assay (Pierce, Rockford,
IL). Equal amounts of proteins were separated on a 12% SDS-
polyacrylamide gel, transferred onto polyvinylidene difluoride
membranes (Sigma-Aldrich), and blocked with PBST (PBS/0.05%
Tween-20; Sigma-Aldrich) containing 5% non-fat dry milk (Bio-Rad,
Hercules, CA; blocking buffer). The membranes were incubated with
0.2 mg ml1 of goat anti-mouse CCL21 polyclonal Ab (R&D Systems)
in blocking buffer overnight at 41C. After extensive washing with
PBST, the membranes were incubated for 45 minutes at RT with a
horseradish peroxidase-conjugated rabbit anti-goat Ab (Bio-Rad)
diluted 1:40,000 in blocking buffer. The membranes were subse-
quently washed in PBST and proteins were visualized using ECL
Western Blotting Detection Reagents (GE Healthcare Europe,
Munich, Germany).
Murine CCL21 concentrations in the cell culture supernatants of
COS-7 cells transfected with pDNA (pVR1012-mCCL21-IRES-EGFP
and pVR1012-IRES-EGFP) were analyzed by mouse CCL21/6Ckine
DuoSet ELISA (R&D Systems) according to the manufacturer’s
instructions.
Gene gun-mediated administration and in vivo expression of
pDNA
Gene gun bullets carrying pDNA were prepared as described by
Tuting et al. (1999). Briefly, pDNA was precipitated onto 1-mm gold
particles (Bio-Rad) at a density of 2 mg of DNA per microgram of
particles. The gold particles and DNA were resuspended in 100 ml of
0.05 M spermidine (Sigma-Aldrich) and DNA was precipitated by
addition of 100ml of 1 M CaCl2 (Merck Chemicals). The particles
were washed with ethanol (VWR International, Vienna,
Austria) to remove H2O, resuspended in ethanol (VWR International)
containing 0.1 mg ml1 polyvinylpyrrolidone (Sigma-Aldrich), and
coated onto the inner surface of Tefzel tubes using a tube loader
(Bio-Rad).
Six- to eight-week-old plt/plt mice were anesthetized by
intraperitoneal injections of Ketalar/Rompun (Hollabrunn mixture;
Bayer AG, Leverkusen, Germany) and three non-overlapping shots of
1mg pVR1012-mCCL21-IRES-EGFP, and control plasmid, respec-
tively, were applied to the shaved skin of the abdomen using an
Accell helium pulse gun (Bio-Rad) at a pressure of 300 pounds per
square inch (psi). After 1, 3, 7, and 14 days of plasmid administration
mice were killed and the abdominal area skin was taken and snap-
frozen in liquid nitrogen. Cryosections measuring 10mm were
prepared and subjected to immunohistochemical staining or direct
immunofluorescence microscopic analysis.
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For immunohistochemistry, the cryosections were transferred
onto glass slides, fixed in 4% paraformaldehyde in PBS
(Invitrogen), washed in PBS/0.5% Triton X-100 (Merck Chemicals),
and unspecific binding sites were blocked using a blocking
solution for 1 hour at RT. Subsequently, the slides were incubated
with a goat anti-mouse CCL21 polyclonal Ab (2mg ml1; R&D
Systems) in blocking solution overnight at 41C and alkaline
phosphatase-conjugated rabbit anti-goat antiserum (Molecular
Probes) for 30 minutes at RT. Reactions were developed using
Fuchsin Substrate-Chromogen (Dako) according to the
manufacturer’s protocol and the sections were counterstained with
hematoxylin. Endogenous alkaline phosphatase was blocked by
incubation with 0.24 mg ml1 of levamisole (Sigma-Aldrich). In
negative controls, the primary Ab was substituted by isotype-
matched IgG.
For immunofluorescence microscopic analysis of EGFP expres-
sion, the cryosections were directly mounted onto glass slides in
Prolong Gold anti-fade reagent (Molecular Probes) and subsequently
evaluated by confocal laser-scanning microscopy.
In vivo expression of transgenic mCCL21 was also confirmed by
ELISA in single-cell suspensions derived from pDNA-treated skin.
The abdominal area skin was collected 24 hours after administration
of pVR1012-mCCL21-IRES-EGFP and pVR1012-IRES-EGFP, minced
in PBS without Caþ þ /Mgþ þ (Invitrogen), digested with 2mg ml1 of
collagenase/dispase (Roche Diagnostics) in PBS without Caþ þ /
Mgþ þ (Invitrogen) for 60 minutes at 371C and with light agitation,
passed through a 70-mm nylon mesh, and centrifuged at 1,500 r.p.m.
for 10 minutes. The cells were resuspended in a culture medium and
cultured for 72 hours in 12-well plates (eBioscience, San Diego,
USA). Thereafter, supernatants were collected and concentrations of
mCCL21 were analyzed by ELISA (R&D Systems) according to the
manufacturer’s instructions.
CCL21’s concentration in the draining inguinal LNs of plt/plt
mice after pVR1012-mCCL21-IRES-EGFP or control pVR1012-IRES-
EGFP application into the abdominal skin was measured using a
mouse CCL21/6Ckine DuoSet ELISA (R&D Systems) according to the
manufacturer’s instructions.
For flow cytometric analysis of CD40 expression by skin
CD11cþ DCs, the abdominal skin was collected 24 hours after
administration of pVR1012-mCCL21 and pVR1012, and a single-cell
suspension was prepared as described earlier. The cells were
resuspended in 2% PBS/BSA supplemented with 10% mouse serum
and 5% goat serum (both from Invitrogen) and incubated for
15 minutes at 41C to block FcgR. Surface expression of CD40
by DCs was determined by flow cytometric analysis using the
following mAbs: FITC-CD11c (HL3) and PE-CD40 (3/23) (both
Ab and the corresponding isotype controls (Armenian hamster
FITC-IgG1 and PE-rat IgG2a) were from BD Biosciences, Vienna,
Austria). Autofluorescent cells were excluded using the FL3
channel.
Cellular composition analysis of PLNs draining pDNA
administration sites
After 3, 7, and 14 days of cutaneous gene gun-mediated adminis-
tration of pVR1012-mCCL21-IRES-EGFP draining, that is, inguinal
PLNs were collected. The tissues were minced, digested with
2mg ml1 of collagenase/dispase (Roche Diagnostics) in PBS without
Caþ þ /Mgþ þ (Invitrogen) for 60 minutes at 371C and under light
agitation, passed through a 70-mm nylon mesh, and centrifuged at
1,500 r.p.m. for 10 minutes. The cells were resuspended in 2% PBS/
BSA supplemented with 10% mouse serum and 5% goat serum (both
from Invitrogen), and incubated for 15 minutes at 41C to block FcgR.
A predetermined number of calibration beads (CaliBRITE Beads; BD
Biosciences) were then added to each sample to allow normalization
of cell counts in different samples and cells were counted using a
FACScan (BD Biosciences) as described by Jahrsdorfer et al. (2005).
The cellular composition was determined by flow cytometric
analysis using the following mAbs: PE-Cy5-CD4 (L3T4), PE-Cy5-
CD8 (53-6.7), FITC-CD11c (HL3), PE-CD62L (MEL-14) (all Abs and
the corresponding isotype controls (PE-rat IgG2a and Armenian
hamster FITC-IgG1) were from BD Biosciences). Autofluorescent
cells were excluded using the FL3 channel.
Adoptive transfer studies
Red blood cell-depleted splenocytes derived from wild-type BALB/c
mice were labeled with CFSE (at a final concentration of 0.2 mM;
Molecular Probes), washed extensively in PBS/5% fetal calf serum,
and resuspended in RPMI/25 mM HEPES (Invitrogen). In general,
labeling efficacy was more than 99%; significant toxicity could be
excluded by staining with propidium iodide (Sigma-Aldrich) and
FACScan analysis (BD Biosciences).
pVR1012-mCCL21-IRES-EGFP and its control vector pVR1012-
IRES-EGFP were administered as described above and 24 hours later
15 106 CFSE-labeled splenocytes were injected into the tail vein of
syngeneic plt/plt mice. The spleens and PLNs draining the plasmid
administration site were obtained 3 hours later. Single-cell suspen-
sions were prepared as described above and analyzed for the
presence of CFSEþ cells by FACScan analysis (BD Biosciences).
Total cells were acquired for 1 minute with steady-state flow rate
followed by counting of CFSEþ cells within the acquired cell
populations. Dead cells were excluded by staining with propidium
iodide (Sigma-Aldrich) and autofluorescent cells by using the FL3
channel.
Statistical analysis
Statistical analysis was performed by unpaired t-test, one-way
ANOVA tests with Tukey post-tests, and Kruskall–Wallis ANOVA
with Dunns’s post-test using the GraphPad-Instat software
(www.graphpad.com).
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